1 Cash-Burning Stock with Solid Fundamentals and 2 We Turn Down

via StockStory

DNUT Cover Image

Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.

Not all companies are worth the risk, and that’s why we built StockStory - to help you spot the red flags. Keeping that in mind, here is one high-risk, high-reward company with the potential to scale into a market leader and two that may struggle to stay afloat.

Two Stocks to Sell:

Krispy Kreme (DNUT)

Trailing 12-Month Free Cash Flow Margin: -4.2%

Famous for its Original Glazed doughnuts and parent company of Insomnia Cookies, Krispy Kreme (NASDAQ:DNUT) is one of the most beloved and well-known fast-food chains in the world.

Why Are We Out on DNUT?

  1. Earnings per share have contracted by 21.6% annually over the last four years, a headwind for returns as stock prices often echo long-term EPS performance
  2. Cash-burning history makes us doubt the long-term viability of its business model
  3. Depletion of cash reserves could lead to a fundraising event that triggers shareholder dilution

At $3.83 per share, Krispy Kreme trades at 154.7x forward P/E. Dive into our free research report to see why there are better opportunities than DNUT.

PacBio (PACB)

Trailing 12-Month Free Cash Flow Margin: -71.2%

Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ:PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness.

Why Are We Wary of PACB?

  1. Sales tumbled by 10.7% annually over the last two years, showing market trends are working against its favor during this cycle
  2. Cash burn makes us question whether it can achieve sustainable long-term growth
  3. Unprofitable operations could lead to additional rounds of dilutive equity financing if the credit window closes

PacBio is trading at $1.57 per share, or 2.8x forward price-to-sales. Read our free research report to see why you should think twice about including PACB in your portfolio.

One Stock to Watch:

Rocket Lab (RKLB)

Trailing 12-Month Free Cash Flow Margin: -53.5%

Becoming the first private company in the Southern Hemisphere to reach space, Rocket Lab (NASDAQ:RKLB) offers rockets designed for launching small satellites.

Why Do We Like RKLB?

  1. Annual revenue growth of 56.9% over the last two years was superb and indicates its market share increased during this cycle
  2. Market share will likely rise over the next 12 months as its expected revenue growth of 42.6% is robust
  3. Rising returns on capital show the company is starting to reap the benefits of its past investments

Rocket Lab’s stock price of $78.79 implies a valuation ratio of 54.9x forward price-to-sales. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.

High-Quality Stocks for All Market Conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.